JP2023549872A5 - - Google Patents

Info

Publication number
JP2023549872A5
JP2023549872A5 JP2023529055A JP2023529055A JP2023549872A5 JP 2023549872 A5 JP2023549872 A5 JP 2023549872A5 JP 2023529055 A JP2023529055 A JP 2023529055A JP 2023529055 A JP2023529055 A JP 2023529055A JP 2023549872 A5 JP2023549872 A5 JP 2023549872A5
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical composition
composition according
section
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023529055A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549872A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/081971 external-priority patent/WO2022106460A2/en
Publication of JP2023549872A publication Critical patent/JP2023549872A/ja
Publication of JP2023549872A5 publication Critical patent/JP2023549872A5/ja
Pending legal-status Critical Current

Links

JP2023529055A 2020-11-18 2021-11-17 ステロイド節約 Pending JP2023549872A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063115286P 2020-11-18 2020-11-18
US63/115,286 2020-11-18
PCT/EP2021/081971 WO2022106460A2 (en) 2020-11-18 2021-11-17 Steroid sparing

Publications (2)

Publication Number Publication Date
JP2023549872A JP2023549872A (ja) 2023-11-29
JP2023549872A5 true JP2023549872A5 (enExample) 2024-07-29

Family

ID=78819991

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023529055A Pending JP2023549872A (ja) 2020-11-18 2021-11-17 ステロイド節約

Country Status (10)

Country Link
US (1) US20240327529A1 (enExample)
EP (1) EP4247423A2 (enExample)
JP (1) JP2023549872A (enExample)
KR (1) KR20230110304A (enExample)
CN (1) CN116997359A (enExample)
AU (1) AU2021383537A1 (enExample)
CA (1) CA3200884A1 (enExample)
IL (1) IL302871A (enExample)
TW (1) TW202241945A (enExample)
WO (1) WO2022106460A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202300382T1 (it) * 2021-04-23 2024-01-10 Astrazeneca Ab Regime di dosaggio anti-ifnar1 per iniezione sottocutanea
EP4616001A1 (en) * 2022-11-09 2025-09-17 Merck Patent GmbH Use of ifn-i activity as a biomarker for tlr inhibitor treatment
WO2025022280A1 (en) * 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
PE20090047A1 (es) 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
ES2643237T3 (es) 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
SMT201700063T1 (it) 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
AU2010323037B2 (en) 2009-11-30 2015-01-29 Biotest Ag Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE)
US20110281374A1 (en) * 2010-05-12 2011-11-17 Rainger George Edward Biomarker
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
EP3867645B1 (en) * 2018-10-18 2024-06-05 Oklahoma Medical Research Foundation Biomarkers for a systemic lupus erythematosus (sle) disease activity immune index that characterizes disease activity
DK4058060T3 (da) * 2019-11-11 2025-03-17 Astrazeneca Ab Type i-interferon-hæmning ved systemisk lupus erythematosus
JP2023527054A (ja) * 2020-05-29 2023-06-26 アストラゼネカ・アクチエボラーグ Ｉ型インターフェロンシグナル伝達の阻害剤による心血管代謝疾患の治療
SMT202300382T1 (it) * 2021-04-23 2024-01-10 Astrazeneca Ab Regime di dosaggio anti-ifnar1 per iniezione sottocutanea

Similar Documents

Publication Publication Date Title
JP6837105B2 (ja) Ｉｌ−４ｒ阻害剤の投与による好酸球性食道炎を治療する方法
EP4114465B1 (en) Anti-ifnar1 dosing regime for subcutaneous injection
JP2023002562A (ja) 抗ｔｌ１ａモノクローナル抗体の中和
JP2026048776A (ja) 炎症性疾患の処置法
CN113876947A (zh) Il-17抗体的药物产品和稳定液体组合物
JP2011526244A (ja) 炎症の処置方法
WO2013148350A2 (en) Anti-light antibody therapy for inflammatory bowel disease
US20030232048A1 (en) Methods for treating chronic obstructive pulmonary disease (COPD)
TW202019477A (zh) BCMAxCD3抗體構建體之給藥方案
KR20210100638A (ko) 호중구 질환을 치료하는 방법
WO2019084307A1 (en) ANTI-MERTK ANTIBODIES AND METHODS OF USE
JP2019536756A (ja) Ｉｌ−２３ａ抗体を用いて疾患を処置する方法
KR20190141148A (ko) 소아 장애를 치료하는 방법
CN115551886A (zh) 用于ttr淀粉样变性的联合疗法
CN112105387A (zh) 特应性皮炎的治疗
CN115667309A (zh) 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病
US20240327529A1 (en) Steroid sparing
JP2020518604A (ja) Ｉｌ−１７アンタゴニストを使用して喘息を選択的に治療する方法
CN119486744A (zh) 艾萨妥昔单抗联合其他药物用于治疗多发性骨髓瘤的用途
JP2022101535A (ja) 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン
JP2022104920A (ja) 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン
JP2024522095A5 (enExample)
JP2023550311A (ja) 多発性骨髄腫の処置のための、イサツキシマブの使用
KR20210060582A (ko) 화농성 한선염 치료를 위한 범-elr+ cxc 케모카인 항체
WO2019011918A1 (en) TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS